Gaining trust through transparency: the EMERGENT-2 trial
- PMID: 39127474
- DOI: 10.1016/S0140-6736(24)01268-6
Gaining trust through transparency: the EMERGENT-2 trial
Comment in
-
Gaining trust through transparency: the EMERGENT-2 trial - Authors' reply.Lancet. 2024 Aug 10;404(10452):524. doi: 10.1016/S0140-6736(24)01269-8. Lancet. 2024. PMID: 39127476 No abstract available.
Comment on
-
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.Lancet. 2024 Jan 13;403(10422):160-170. doi: 10.1016/S0140-6736(23)02190-6. Epub 2023 Dec 14. Lancet. 2024. PMID: 38104575 Clinical Trial.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
